Registration on ClinicalTrials.gov is a requirement for all National Institutes of Health (NIH)-funded clinical trials and all Food and Drug Administration (FDA) “Applicable Clinical Trials." This ...

Net Loss: Net loss attributable to common stockholders for the third quarter of 2024 was $ (3.1) million, or $ (1.92) per share, compared to net income of $0.5 million, or $4.86 per share, for the ...

For unresectable or metastatic liver cancer, the TPST-1120-301 trial of amezalpat combination therapy has received a “Study ...

The Food and Drug Administration (FDA) has granted accelerated approval to Kebilidi™ (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid ...

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

“The study is expected to be completed in the first quarter of next year according to clinicaltrials.gov and could provide ...

Phase 3 PIVOT-PO trial of tebipenem HBr remains on track to complete enrollment in 2H 2025Reiterate cash runway into mid-2026; Q3 2024 ending ...

Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics ...

Palatin Technologies, Inc. ( NYSE: PTN) Q1 2025 Earnings Conference Call November 14, 2024 11:00 AM ET Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secretary ...

Nipocalimab was well-tolerated over the six-month study period, with no major safety signals observed. The most common adverse events (AEs) were infections and infestations: 60.4% (n=32) in the ...